Each year, Unitec awards a maximum of two innoLIFE subsidies of up to CHF 100,000 each for the maturation of inventions developed at UNIGE in the healthcare field. The innoLIFE fund is fed by income from licenses granted by the UNIGE to third parties for the commercial exploitation of technologies developed at the UNIGE. innoLIFE subsidies exclusively support projects with applications in the healthcare sector (pharma, biotech or medtech), whether through the creation of a spin-off or through a license to an existing company. innoLIFE grants are designed to finance primarily the acquisition of goods and/or services, either from UNIGE technology platforms or from external third parties. For example: - the acquisition of compounds, libraries or services for molecular screening; - acquisition of preclinical services (ADME/tox, PK studies); - generation of antibodies or siRNA against a therapeutic target; - prototyping or development of software/interfaces for a medical device, etc. The use of innoLIFE funds for the acquisition of laboratory equipment may not exceed one third of the awarded amount, and any equipment purchased must be necessary for the successful execution of the commercialisation project, not be available elsewhere at UNIGE, and be primarily used for translational projects. innoLIFE funds may exceptionally cover salaries if: - there is no other source of funding available for the project; and - the project is well-defined and specifically aimed at technology transfer; and - the project deliverables are precisely defined
